2016 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2020 | 0 | 8.573.895 | 0 | 1 | ||
2016 | 0 | 6.000.000 | 467.344 | 1 | ||
2012 | 0 | 4.050.255 | 675.043 | 1 |
Total number of partners: 32
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 32
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2020-04-01 | COMBINING APPROACHES FOR PHOTOSYNTHETIC IMPROVEMENT TO ALLOW INCREASED SUSTAINABILITY IN EUROPEAN AGRICULTURE | CAPITALISE | participant | 8.573.895 | 21 |
2016-01-01 | VISION-DMD - Phase 2 Clinical Trials of VBP15: An Innovative Steroid-like Intervention on Duchenne Muscular Dystrophy | VISION DMD | participant | 6.000.000 | 8 |
2012-12-01 | Orphan Drug for Acanthamoeba Keratitis | ODAK | participant | 4.050.255 | 6 |